| Autor: |
Beau Bruneau, Kristin Surdam, Amy Bland, Amy Krueger, Andrew Wise, Ani Cotarlan, Asher Leviton, Elena Jouravleva, Grace Fitzgerald, Heather N. Frost, Honora F. Cutler, Joshua Buddle, Luis G. Diaz, Michele Cohen, Nancy A. Sacco, Ryan Washington, Susan Mauermann, Victor Chen, Andrea Bastek |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Contemporary Clinical Trials Communications, Vol 40, Iss , Pp 101291- (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2451-8654 |
| DOI: |
10.1016/j.conctc.2024.101291 |
| Popis: |
Background: This Site Feasibility Task Force convened to assess the complex and burdensome process of site feasibility in clinical trials. The objective was to create mutual understanding of challenges and provide suggestions for improving collaboration among sponsors, contract research organizations (CROs), and sites. Methods: The task force was composed of representatives from sponsors, CROs and sites (43 % Sites, 20 % Site Networks, 10 % Small/mid-size sponsors, 10 % Small/mid-size CROs, 10 % Large sponsors, 7 % Large CROs). The group collaborated to define the scope of the problem, identify challenges in the current process, and provide suggestions for improving the process. Results: The group found there is a need for better differentiation between the three main stages of feasibility, and the four sub-phases of Site Feasibility. The discussion brought to light emerging trends like early initiation of Site Feasibility and premature engagement of sites by CROs. To fully explain these challenges, the group analyzed the current practices and documented their downstream impact on clinical trial execution for all stakeholders. A list of best practices emerged naturally from this analysis. These findings are aggregated into short and actionable best practice guides. Conclusion: The task force suggests practical changes for the feasibility process and raises awareness of emerging trends and their associated risks. This awareness can begin to drive change in the site feasibility process, although industry-wide transformation will require new levels of collaboration, data standardization and automation tools. The potential benefits of evolving this process are significant and meaningful for more efficient and successful clinical trials. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
